Study on bioequivalence of beraprost in healthy volunteers by liquid chromatography with tandem mass spectrometry

Budi Prasaja, Yahdiana Harahap, Windy Lusthom, Anna Sofiana, Falah Safira, Monika Sandra, Girinanda Puspanegara

Research output: Contribution to journalArticlepeer-review

Abstract

Beraprost sodium is an oral prostacyclin analog that was first approved in 1992 (Japan) for the treatment of peripheral vascular disorders. It is administered orally as a tablet available in strength 20 μg. In this paper, we described a liquid chromatography tandem mass spectrometry method that was developed for the quantification of beraprost in human plasma with high sensitivity at picogram per milliliter concentration. The method had been validated in terms of selectivity, sensitivity, accuracy and precision, matrix effect, linearity, recovery and carry-over according to the Guideline on Bioanalytical Validation from the European Medicines Agency. The standard calibration curve for beraprost was 9.5–1419 pg/mL. This method has been applied successfully to a bioequivalence study with 60 μg of beraprost (three tablets) in 29 healthy volunteers. The results showed that the two formulations of beraprost are bioequivalent.

Original languageEnglish
Article numbere4403
JournalBiomedical Chromatography
Volume33
Issue number2
DOIs
Publication statusPublished - 1 Feb 2019

Keywords

  • LC–MS/MS
  • antiplatelet
  • beraprost
  • bioequivalence
  • pharmacokinetic

Fingerprint Dive into the research topics of 'Study on bioequivalence of beraprost in healthy volunteers by liquid chromatography with tandem mass spectrometry'. Together they form a unique fingerprint.

Cite this